NASDAQ:RNAZ

TransCode Therapeutics Stock Forecast, Price & News

$3.28
+0.11 (+3.47 %)
(As of 08/4/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.05
$3.33
50-Day Range N/A
52-Week Range
$2.67
$7.00
Volume394,607 shs
Average Volume2.26 million shs
Market Capitalization$39.25 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive RNAZ News and Ratings via Email

Sign-up to receive the latest news and ratings for TransCode Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


TransCode Therapeutics logo

About TransCode Therapeutics

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

1186th out of 1,311 stocks

Pharmaceutical Preparations Industry

584th out of 647 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











TransCode Therapeutics (NASDAQ:RNAZ) Frequently Asked Questions

What stocks does MarketBeat like better than TransCode Therapeutics?

Wall Street analysts have given TransCode Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TransCode Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Who are TransCode Therapeutics' key executives?

TransCode Therapeutics' management team includes the following people:
  • Mr. Robert Michael Dudley, Co-Founder, CEO & Director (Age 70)
  • Dr. Zdravka Medarova Ph.D., Co-Founder & VP of Drug Discovery (Age 46)
  • Dr. Anna Moore Ph.D., Co-Founder & Member of Scientific Advisory Board (Age 59)
  • Mr. Thomas A. Fitzgerald M.B.A., CFO, VP & Director (Age 69)
  • Dr. Judy Carmody, VP of Operations (Age 54)
  • Dr. Qiyong Peter Liu, Chief Scientist (Age 57)

Who are some of TransCode Therapeutics' key competitors?

When did TransCode Therapeutics IPO?

(RNAZ) raised $25 million in an initial public offering (IPO) on Friday, July 9th 2021. The company issued 6,250,000 shares at $4.00 per share.

What is TransCode Therapeutics' stock symbol?

TransCode Therapeutics trades on the NASDAQ under the ticker symbol "RNAZ."

When does TransCode Therapeutics' quiet period expire?

TransCode Therapeutics' quiet period expires on Wednesday, August 18th. TransCode Therapeutics had issued 6,250,000 shares in its initial public offering on July 9th. The total size of the offering was $25,000,000 based on an initial share price of $4.00. During TransCode Therapeutics' quiet period, insiders and underwriters involved in the IPO are prevented from issuing any research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

How do I buy shares of TransCode Therapeutics?

Shares of RNAZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TransCode Therapeutics' stock price today?

One share of RNAZ stock can currently be purchased for approximately $3.28.

How much money does TransCode Therapeutics make?

TransCode Therapeutics has a market capitalization of $39.25 million.

How many employees does TransCode Therapeutics have?

TransCode Therapeutics employs 2 workers across the globe.

What is TransCode Therapeutics' official website?

The official website for TransCode Therapeutics is www.transcodetherapeutics.com.

Where are TransCode Therapeutics' headquarters?

TransCode Therapeutics is headquartered at 6 LIBERTY SQUARE 2382, BOSTON MA, 02109.

How can I contact TransCode Therapeutics?

TransCode Therapeutics' mailing address is 6 LIBERTY SQUARE 2382, BOSTON MA, 02109. The company can be reached via phone at 857-837-3099.


This page was last updated on 8/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.